Adenoscan is a drug owned by Astellas Pharma Us Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 24, 2015. Details of Adenoscan's patents and their expiration are given in the table below.
Filter patents by
Country
: United States (US)
Argentina (AR)
Australia (AU)
Brazil (BR)
Canada (CA)
Chile (CL)
China (CN)
India (IN)
Japan (JP)
Mexico (MX)
Paraguay (PY)
Philippines (PH)
Russia (RU)
Singapore (SG)
South Africa (ZA)
Thailand (TH)
United States (US)
Uruguay (UY)
Eurasian Patent Organization (EA)
World Intellectual Property Organization (WO)
Taiwan (TW)
European Patent Office (EP)
Patent Category
: All
All
Combination
Compound
Device
Dosage Regimen
Formulation
Other Forms
Polymorph
Process
Use Method
Dosage Form Category
: Others
Implantable
Inhalation
Injectable
OPHTHALMIC
Oral Liquid
Oral Solid
Rectal/Vaginal
Topical
Transdermal
Others
NEW
Get the complete list right in your inbox!
Contact Us
Drug Patent Number
Drug Patent Title
Drug Patent Expiry
Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration
(oral, tablet,
capsules, liquids etc).
Selective vasodilation by continuous adenosine infusion
Mar, 2015
(11 years ago)
Expired
Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.
Get the exclusive patent insights now. Don't be the last to know.
US patents provide insights into the exclusivity only within the United States, but
Adenoscan is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Adenoscan's family patents as well as insights into
ongoing legal events
on those patents.
Adenoscan's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Adenoscan:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Adenoscan's
generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 24, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Adenoscan Generic
API
suppliers:
Adenosine is the generic name
for
the brand Adenoscan.
15 different companies have already filed for the generic of Adenoscan, with Fresenius Kabi Usa having the maximum number of approved applications.
Check out the entire list of companies
who have already received approval for Adenoscan's
generic
How can I launch a generic of Adenoscan before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before
the expiration of Adenoscan's patents related
by providing a 'paragraph IV certification' in your
application, which states that the patent submitted by the
Adenoscan's sponsor is invalid, unenforceable,
or will not be infringed by your generic product.
Given below are the details of the already filed Para IV
certificates on Adenoscan -
Adenoscan is a drug owned by Astellas Pharma Us Inc. It is used for improving blood flow in certain areas of the body. Adenoscan uses Adenosine as an active ingredient. Adenoscan was launched by Astellas in 1995.
Approval Date:
Adenoscan was approved by
FDA for market
use on 18 May, 1995.
